103P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of Chinese extensive-stage small cell lung cancer (ORIENTAL): Preliminary safety and efficacy results. (December 2022) - Cheng, Y.; Wang, J.; Yu, Y.; Zang, A.; Lv, D.; Li, S.; Cao, L.; Meng, Z.; Mao, W.D.; Zhang, J.; Liu, A.; Zhang, Y.; et al.